HonorHealth Research Institute announced that the first patients have been enrolled in the SynIVUS-DAPT Study, a clinical study designed to test outcomes of decreasing the amount of time patients, with a high risk of bleeding, take antiplatelet medications after receiving a drug-eluting coronary stent.Continue reading
Category Archives: AZBio News
Flinn Foundation Selects 20 Excelling Arizona High-School Seniors as 2019 Flinn Scholars
Twenty of Arizona’s highest-achieving high-school seniors have been named Flinn Scholars and will receive scholarships to Arizona’s three public research universities valued at more than $120,000.Continue reading
INSYS Therapeutics Implements Leadership Changes
PHOENIX, April 15, 2019 — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company.Continue reading
bioSyntagma Named Finalist for Global Sustainability Award
Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards, which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients.Continue reading
New techniques may detect CTE in brains of living former NFL players
Arizona researchers are playing a key role in the search for new ways to identify CTE before death. In a study released online in the New England Journal of Medicine, a cross-national team, including local researchers from Arizona State University, Banner Alzheimer’s Institute, the Mayo Clinic College of Medicine, and Boston University have brought us a step closer to diagnosing CTE in living, former NFL players.Continue reading
C-Path Receives Qualification from FDA for the Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD)
TUCSON, Ariz., April 9, 2019 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces U.S. Food and Drug Administration (FDA) qualification of two new clinical outcome assessment tools: the Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD). The qualification of the ADSD and the ANSD represents a major milestone for the PRO Consortium and specifically for the Asthma Working Group. It is the culmination of a multi-year collaboration between FDA’s Center for Drug Evaluation and Research (CDER) and the PRO Consortium.
Senator Sinema Honored as Innovator in Biotechnology
Washington, D.C. (April 3, 2019) – Senator Kyrsten Sinema was recognized today by the Biotechnology Innovation Organization (BIO) for her leadership as an Innovator in Biotechnology. Senator Sinema received the award in conjunction with today’s BIO Legislative Day Fly-In.Continue reading
Exploring Copper’s Potential as Antibiotic
While antibiotic resistance is on the rise, pharmaceutical companies are making fewer and fewer new antibiotics. UA immunobiologist Michael Johnson says this trend is in urgent need of reversal and believes copper might just be the key.Continue reading
C-Path President and CEO, Board Director Selected to Serve on Esteemed National Academies of Sciences, Engineering and Medicine Committee
C-Path President and CEO Martha Brumfield, PhD, and C-Path Board Director Alastair J. Wood, MD, FRCP, have both been selected to the serve on the National Academy Consensus Committee examining Mutual Recognition Agreements in the Regulation of Medicines under The National Academies of Sciences, Engineering and Medicine. Dr. Wood will serve as chair.